| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5565133 | Complementary Therapies in Medicine | 2017 | 24 Pages |
Abstract
Silymarin was effective in decreasing serum OS and enhancing serum antioxidant capability in patients with β-thalassemia major. Silymarin given as an adjuvant therapy to standard iron chelators may provide an improvement in the OS measurements obtained in these patients, with accompanying benefit.
Keywords
MDAIRCTTRCTACTBARSTBAFRAPGSHGPXROSβ-thalassemia majorAntioxidantThiobarbituric acidPolyunsaturated fatty acidPUFAOxidative stressSODSuperoxide dismutaseSilymarinTotal antioxidant capacitymalondialdehydethiobarbituric acid reactive substancesIron overloadFSHferric reducing/antioxidant powerreduced glutathioneprotein carbonylglutathione peroxidaseReactive oxygen species
Related Topics
Health Sciences
Medicine and Dentistry
Complementary and Alternative Medicine
Authors
Hadi Darvishi-Khezri, Ebrahim Salehifar, Mehrnoush Kosaryan, Hossein Karami, Abbas Alipour, Fatemeh Shaki, Aily Aliasgharian,